# A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

> **NCT04814186** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 53 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Tafamidis

## Key facts

- **NCT ID:** NCT04814186
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-22
- **Primary completion:** 2023-10-16
- **Final completion:** 2023-10-16
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04814186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04814186, "A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04814186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*